Fluticasone/salmeterol combination confers benefits in people with asthma who smoke

Chest

Volumn 141, Issue 2, 2012, Pages 330-338

  Clearie, Karine L ^a   McKinlay, Lorna ^a   Williamson, Peter A ^a   Lipworth, Brian J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; PLACEBO;

ADULT; AGED; ARTICLE; ASTHMA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; SMOKING;

EID: 84856731820     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.11-0392     Document Type: Article

References (32)

1. Lange P, Parner J, Vestbo J, Schnohr P, Jensen G. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med. 1998;339(17):1194-1200.
2. Siroux V, Pin I, Oryszczyn MP, Le Moual N, Kauffmann F. Relationships of active smoking to asthma and asthma severity in the EGEA study. Epidemiological study on the Genetics and Environment of Asthma. Eur Respir J. 2000;15(3):470-477. (Pubitemid 30158183)
3. Sippel JM, Pedula KL, Vollmer WM, Buist AS, Osborne ML. Associations of smoking with hospital-based care and quality of life in patients with obstructive airway disease. Chest. 1999;115(3):691-696. (Pubitemid 29129946)
4. Willemse BW, ten Hacken NH, Rutgers B, Lesman-Leegte IG, Timens W, Postma DS. Smoking cessation improves both direct and indirect airway hyperresponsiveness in COPD. Eur Respir J. 2004;24(3):391-396. (Pubitemid 39232261)
5. Chalmers GW, Macleod KJ, Little SA, Thomson LJ, McSharry CP, Thomson NC. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax. 2002;57(3):226-230. (Pubitemid 34214408)
6. Thomson NC, Chaudhuri R, Livingston E. Asthma and cigarette smoking. Eur Respir J. 2004;24(5):822-833. (Pubitemid 39504438)
7. Tomlinson JE, McMahon AD, Chaudhuri R, Thompson JM, Wood SF, Thomson NC. Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma. Thorax. 2005;60(4):282-287. (Pubitemid 40522363)
8. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Arch Intern Med. 1999;159(9):941-955. (Pubitemid 29222495)
9. Pedersen SE, Bateman ED, Bousquet J, Busse WW, Yoxall S, Clark TJ; Gaining Optimal Asthma controL Steering Committee and Investigators. Determinants of response to fluticasone propionate and salmeterol/fluticasone propionate combination in the Gaining Optimal Asthma controL study. J Allergy Clin Immunol. 2007;120(5):1036-1042. (Pubitemid 350029898)
10. Jackson C, Lipworth B. Benefits of combination therapy on exacerbations in nonsmoking patients with asthma. J Allergy Clin Immunol. 2008;121(3):780, author reply 780.
11. Clearie KL, Williamson PA, Vaidyanathan S, Du Bois J, Nell H, Lipworth BJ. Systemic bioavailability of hydrofluoroalkane (HFA) formulations of fluticasone/salmeterol in healthy volunteers via pMDI alone and spacer. Br J Clin Pharmacol. 2010;69(6):637-644.
12. Nair A, Clearie K, Menzies D, Meldrum K, McFarlane L, Lipworth BJ. A novel breath-actuated integrated vortex spacer device increases relative lung bioavailability of fluticasone/ salmeterol in combination. Pulm Pharmacol Ther. 2009;22(4):305-310.
13. American Thoracic Society; European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med. 2005;171(8):912-930.
14. Crapo RO, Casaburi R, Coates AL, et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med. 2000;161(1):309-329.
15. Anderson SD, Brannan J, Spring J, et al. A new method for bronchial-provocation testing in asthmatic subjects using a dry powder of mannitol. Am J Respir Crit Care Med. 1997;156(3 pt 1):758-765. (Pubitemid 27396412)
16. Miller MR, Hankinson J, Brusasco V, et al ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005;26(2):319-338. (Pubitemid 41079078)
17. Oostveen E, MacLeod D, Lorino H, et al ERS Task Force on Respiratory Impedance Measurements. The forced oscillation technique in clinical practice: Methodology, recommendations and future developments. Eur Respir J. 2003;22(6):1026-1041. (Pubitemid 37540659)
18. Lipworth BJ, Seckl JR. Measures for detecting systemic bio-activity with inhaled and intranasal corticosteroids. Thorax. 1997;52(5):476-482. (Pubitemid 27278148)
19. Currie GP, Stenback S, Lipworth BJ. Effects of fluticasone vs. fluticasone/salmeterol on airway calibre and airway hyperresponsiveness in mild persistent asthma. Br J Clin Pharmacol. 2003;56(1):11-17. (Pubitemid 36886483)
20. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ. 2000;320(7246):1368-1373. (Pubitemid 30261116)
21. Pauwels RA, Löfdahl CG, Postma DS, et al Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. Effect of inhaled formoterol and budesonide on exacerbations of asthma [published correction appears in N Engl J Med. 1998;338(2):139]. N Engl J Med. 1997;337(20):1405-1411. (Pubitemid 27497887)
22. British Thoracic Society Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma. Thorax. 2008;63(suppl 4):iv1-iv121.
23. Sont JK, Han J, van Krieken JM, et al. Relationship between the inflammatory infiltrate in bronchial biopsy specimens and clinical severity of asthma in patients treated with inhaled steroids. Thorax. 1996;51(5):496-502. (Pubitemid 26160470)
24. Sovijärvi AR, Haahtela T, Ekroos HJ, et al. Sustained reduction in bronchial hyperresponsiveness with inhaled fluticasone propionate within three days in mild asthma: Time course after onset and cessation of treatment. Thorax. 2003;58(6):500-504. (Pubitemid 36714011)
25. van den Berge M, Kerstjens HA, Meijer RJ, et al. Corticosteroid-induced improvement in the PC20 of adenosine monophosphate is more closely associated with reduction in airway inflammation than improvement in the PC20 of methacholine. Am J Respir Crit Care Med. 2001;164 (7):1127-1132. (Pubitemid 33052238)
26. Currie GP, Bates CE, Lee DK, Jackson CM, Lipworth BJ. Effects of fluticasone plus salmeterol versus twice the dose of fluticasone in asthmatic patients. Eur J Clin Pharmacol. 2003;59(1):11-15. (Pubitemid 36702753)
27. Currie GP, Haggart K, Brannan JD, Lee DK, Anderson SD, Lipworth BJ. Relationship between airway hyperresponsiveness to mannitol and adenosine monophosphate. Allergy. 2003;58(8):762-766. (Pubitemid 36920466)
28. Sindi A, Todd DC, Nair P. Antiinflammatory effects of long-acting beta2-agonists in patients with asthma: A systematic review and metaanalysis. Chest. 2009;136(1):145-154.
29. Currie GP, Jackson CM, Ogston SA, Lipworth BJ. Airway-stabilizing effect of long-acting beta2-agonists as add-on therapy to inhaled corticosteroids. QJM. 2003;96(6):435-440. (Pubitemid 36675790)
30. Piccillo G, Caponnetto P, Barton S, et al. Changes in airway hyperresponsiveness following smoking cessation: comparisons between Mch and AMP. Respir Med. 2008;102(2):256-265. (Pubitemid 350296906)
31. Oppenheimer BW, Goldring RM, Herberg ME, et al. Distal airway function in symptomatic subjects with normal spirometry following World Trade Center dust exposure. Chest. 2007;132(4):1275-1282. (Pubitemid 47621004)
32. Kharitonov SA, Robbins RA, Yates D, Keatings V, Barnes PJ. Acute and chronic effects of cigarette smoking on exhaled nitric oxide. Am J Respir Crit Care Med. 1995;152(2):609-612.